David
Co-Founder
I recently asked our panel of experts:
Dr. Marc E. Schaefer, MD, MPH of the Penn State Hershey Inflammatory Bowel Disease Center took time out of his busy schedule to answer this question. A little about Dr. Schaefer:
Marc Schaefer is a board certified pediatric gastroenterologist who has been practicing at Penn State Hershey Children's Hospital since 2009. Dr. Schaefer is active in inflammatory bowel disease clinical research at Penn State Hershey Medical Center, including participation in the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry, the PROKIIDS Pediatric Inflammatory Bowel Disease Research Network, and ImproveCareNow, which is a health network focused on quality improvement in pediatric inflammatory bowel disease. He also participates in the Hershey Medical Center IBD support group. Dr. Schaefer received his medical degree from Sackler School of Medicine-New York State American Branch. He completed his pediatric residency training at Maimonides Medical Center, Infants and Children's Hospital of Brooklyn and Pediatric Gastroenterology and Nutrition fellowship and Masters in Public Health at Hasbro Children's Hospital/Brown University Medical School.
In regards to the question, Dr. Schaefer stated:
Thank you to Dr. Schaefer for his time and expertise!
What is your opinion on the use of mesalamine in Crohn's disease? Should it ever be the only medication someone with Crohn's disease is put on? If yes, what study or studies do you feel support this treatment choice?
Dr. Marc E. Schaefer, MD, MPH of the Penn State Hershey Inflammatory Bowel Disease Center took time out of his busy schedule to answer this question. A little about Dr. Schaefer:
Marc Schaefer is a board certified pediatric gastroenterologist who has been practicing at Penn State Hershey Children's Hospital since 2009. Dr. Schaefer is active in inflammatory bowel disease clinical research at Penn State Hershey Medical Center, including participation in the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry, the PROKIIDS Pediatric Inflammatory Bowel Disease Research Network, and ImproveCareNow, which is a health network focused on quality improvement in pediatric inflammatory bowel disease. He also participates in the Hershey Medical Center IBD support group. Dr. Schaefer received his medical degree from Sackler School of Medicine-New York State American Branch. He completed his pediatric residency training at Maimonides Medical Center, Infants and Children's Hospital of Brooklyn and Pediatric Gastroenterology and Nutrition fellowship and Masters in Public Health at Hasbro Children's Hospital/Brown University Medical School.
In regards to the question, Dr. Schaefer stated:
Dr. Schaefer said:The role of mesalamine in inducing remission of active Crohn's disease and preventing relapse is uncertain. In patients with mild disease, mesalamine is used as monotherapy and it is difficult to predict which patients will do fine on mesalamine monotherapy for a prolonged period of time and which patients will develop a relapse. In patients with moderate to severe Crohn's disease it is felt that other therapies, such as corticosteroids and biologic therapies, are more effective for inducing remission (1). There are at least four studies (2-5) that report a benefit of maintenance therapy with 5-ASA in quiescent (inactive) Crohn's disease. The majority of meta-analyses, including the most recent systematic review of the Cochrane central register of controlled trials reported no benefit of mesalamine over placebo, as well as mesalamine not being effective in preventing quiescent Crohn's disease relapse (1). The most recent Cochrane database systematic review (6) reports a benefit of sulfasalzaine inducing remission in patients mainly with Crohn's colitis (7).
1. Ford AC, Kane SV, Khan KJ et al. Efficacy of 5-aminosalicylates in Crohn's disease: a systematic review and meta-analysis.
Am J Gastroenterol 2011; 106:617-29.
2 . Camma C , Giunta M , Rosselli M et al. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables . Gastroenterology 1997 ; 113 : 1465 – 73 .
3 . Messori A , Brignola C , Trallori G et al. Eff ectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn’s disease: a metaanalysis . Am J Gastroenterol 1994 ; 89 : 692 – 8 .
4 . Steinhart AH , Hemphill D , Greenberg GR . Sulfasalazine and mesalazine for the maintenance therapy of Crohn’s disease: a meta-analysis . Am J Gastroenterol
1994 ; 89 : 2116 – 24 .
5 . Steinhart AH , Forbes A , Mills EC et al. Systematic review: the potential infl uence of mesalazine formulation on maintenance of remission in Crohn’s disease . Aliment Pharmacol Th er 2007 ; 25 : 1389 – 99
6. Lim WC, hanauer S. Aminosalicylates for induction or response in Crohn's disease. Cochrane Database Syst Rev 2010; 12:
7. Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol 2001;96(3):635–43.
Thank you to Dr. Schaefer for his time and expertise!